@Statofish
Account based inBulgaria
About this account
- Account based in
- Bulgaria
- Connected via
- United Kingdom App Store
Account-level information from X, not a live location or the device used for a specific post.
Fibroscan specialist , Nurse consultant, FRCP, advocate and passionate about Liver health and wellness. Co-host @surfing_Mash podcast - my views are my own
United Kingdom
Joined April 2015
- Tweets792
- Following415
- Followers255
- Likes2.6K
🌍 REAL PEOPLE. REAL CHANGE. 5 CONTINENTS.
A FibroScan is a moment in time. What happens next matters.
MyLife365.Me lets people log their scan, track change and stay engaged with their #liverhealth — and it's already reaching people across 5 continents.
#livertwitter
🤖 Made with AI
Louise Campbell retweeted
This is a high quality patient education tool to support people living with #MASH and to help them understand why liver health matters in the context of cardiometabolic risk. I was honored to be a medical advisor on this project.
online.flippingbook.com/view…
Louise Campbell retweeted
Thrilled to be heading to Chicago for #ENDO2026 where I’ll be presenting “MASLD Integrated Management: Lifestyle, Comorbidities, and Cardiovascular Risk” on June 15. Looking forward to discussing MASLD, obesity, and cardiometabolic risk with colleagues from around the world.
Louise Campbell retweeted
And history has been made.
The World Health Assembly resolution on steatotic liver disease passed. A huge thanks to WHO Member States, the Global Think-tank on Steatotic Liver Disease and all our partners and supporters
linkedin.com/posts/global-th…
#ActOnNCDs #SLDthinktank
Thank you for covering liver health. Next week is a turning point with the World Health Assembly resolution on steatotic liver disease expected to pass. I'll be in GVA on Monday in case you can meet.
healthaffairs.org/content/fo…
Louise Campbell retweeted
📢Special Topic: Heart–Liver Integrated Management in Metabolic Disorders
Exploring mechanisms, diagnostics, and treatments at the intersection of cardiovascular and liver disease in metabolic dysfunction.
Submit by 31 Aug 2026 oaepublish.com/specials/mtod…
#Metabolism #CardioHepatic
Louise Campbell retweeted
Inflammation as a therapeutic target in obesity-related disease
The purinergic P2X7 receptor drives inflammasome activation and meta-inflammation, linking obesity with cardiovascular, kidney, and liver complications
oaepublish.com/articles/mtod…
#Obesity #Inflammation #CardioMetabolic
Louise Campbell retweeted
The UPF industry and those they pay frequently claim that criticising harmful food generates shame and stigma. What this series makes unequivocally clear is that the true source of shame/stigma around diet related disease is a food environment that forces so many people to eat harmful food. If you are living with diet related disease just remember - it’s not you, it’s the food
ALD and MetALD are driving a growing global burden of chronic liver disease, and the way we approach care is changing fast.
At #EASLCongress 2026, this forward thinking session will offer a powerful preview of what the next generation of care could look like.
From biomarker led risk stratification and multi omic profiling, to targeted pharmacological, nutritional and behavioural strategies, discover how precision medicine is reshaping the full disease continuum. The session will also highlight the rise of digital hepatology and mobile health tools, showing how scalable technologies can improve adherence, widen access and help reduce disparities.
If you are working in hepatology, metabolic health or digital innovation, this is one to add to your agenda!
👉Register now and secure your place. easlcongress.eu/2026-registr…
@DebbieShawcros1 @analleo
Louise Campbell retweeted
People living with obesity describe mental health as both a driver and consequence of weight, with trauma, stigma and “not fitting in” shaping daily life; this study argues for integrated psychological support as core obesity care, not an optional add‑on.
nature.com/articles/s41366-0…
Louise Campbell retweeted
Impact of Semaglutide 2.4 mg on body composition and function: The SEMALEAN study shows 13% weight loss at 12 months with preserved lean mass, improved grip strength, and reduced sarcopenic obesity. Functional and metabolic health improved alongside fat loss.
dom-pubs.onlinelibrary.wiley…
Louise Campbell retweeted
“Diet” foods aren’t always your friend when it comes to weight loss. Ultra-processed products like gluten-free snacks, fake meats, vegan cheeses, and protein bars can pack excess calories, sugars, and unhealthy fats - often undermining goals.
Read my full comments on @Medscape:
medscape.com/viewarticle/whe…
Adding @MyLife365_Me the FREE #liver #health app in 40 countries enables those who want to get tips and tricks that are #liver focused #MASLD #MASH #fattyliver
Aging brings new reasons to act with intention. Metabolic diseases like MASLD and MASH can progress silently, but early action makes all the difference. At Akero, we’re committed to building a future where people can age with strength and clarity. #HealthyAgingMonth
Louise Campbell retweeted
(3/3) Read our press release for full details: prnewswire.com/apac/news-rel…
#FibroScanVCTE #MASH #ClinicalTrials #DrugDevelopment #LiverHealthMatters
Louise Campbell retweeted
(2/3) This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development—making participation in clinical trials less burdensome and more accessible for people living with MASH.
Louise Campbell retweeted
(1/3) ✨Exciting news in liver health: the FDA has accepted Echosens’ Letter of Intent to qualify LSM by VCTE (FibroScan®) as the first non-invasive surrogate endpoint in MASH clinical trials.
Louise Campbell retweeted
🧬 Study shows MASLD shares key genes & pathways with diabetes, obesity, and lipids—offering new drug targets.
🔗 oaepublish.com/articles/mtod…
#MASLD #Genetics #DrugDiscovery #LiverResearch
Louise Campbell retweeted
The EASL Studio is back! Tune in this Wednesday 18:00 CEST as the faculty explore the relevance of alkaline phosphatase response, non-invasive fibrosis assessment, and composite scores like GLOBE and UK-PBC.
Read more: easl.eu/easl-studio-episode/…
@MCarbone_80 @FrancqueSven
#LiverTwitter #LiverX
Louise Campbell retweeted
🔥 Beyond the liver: Metabolic and sex-specific factors may hold the key to personalized MASLD treatments. Time to rethink one-size-fits-all care!
🔗 oaepublish.com/articles/mtod…
#MASLD #MetabolicHealth #PrecisionMedicine #LiverResearch
The opportunity to translate the numbers seen on gaining a #Fibroscan and the discussion these initiate can be and are often life changing for many individuals
Seeing the empowerment of an individual to address their health is a privilege and a rewarding experience
